After a median follow-up of 2.3 years, methotrexate failed to decrease the incidence of the primary endpoint (myocardial infarction or non-fatal stroke or cardiovascular death) and did not reduce CRP, IL-6, or IL-1β plasma levels. The gene discussed is CRP; the disease is myocardial infarction.